NICOLE RAE: Open Payments
NPI 1487804852 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,066 in 34 payments from 13 companies in 2025. Trend: 2023 $887 · 2024 $1,240 · 2025 $1,066
Food & beverage: $867Education: $199
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $286 |
| SANOFI-AVENTIS U.S. LLC | 2 | $199 |
| Novartis Pharmaceuticals Corporation | 6 | $125 |
| GENZYME CORPORATION | 4 | $111 |
| Grifols USA, LLC | 2 | $63 |
| CSL Behring | 2 | $52 |
| Genentech USA, Inc. | 2 | $42 |
| Cycle Pharmaceuticals Inc | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Pharming Healthcare, Inc. | 1 | $30 |
Products named: DUPIXENT, FASENRA, TEZSPIRE, Xolair, BREZTRI, Sajazir, Xembify, RUCONEST.
Industry payments across CO — which companies pay providers there.
